Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer

Mutagenesis

Volumn 26, Issue 3, 2011, Pages 371-383

  Li, Xia ^a   Huang, Yan ^a   Fu, Xuping ^a   Chen, Chengwen ^a   Zhang, Deqiang ^a   Yan, Lili ^a   Xie, Yi ^a   Mao, Yanjun ^b   Li, Yao ^a  

^a FUDAN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 2;

ALLELE; ARTICLE; CANCER RISK; DOMINANT GENE; GENETIC MODEL; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RECESSIVE GENE;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MEMBRANE PROTEINS; MODELS, GENETIC; ODDS RATIO; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS;

EID: 79955375240     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/geq103     Document Type: Article

References (59)

1. Crawford, E. D. (2009) Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology, 73, S4-S10.
2. Boger-Megiddo, I., Weiss, N. S., Barnett, M. J., Goodman, G. E. and Chen, C. (2008) V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev., 17, 286-291. (Pubitemid 351272777)
3. Chang, B. L., Zheng, S. L., Isaacs, S. D., Turner, A. R., Bleecker, E. R., Walsh, P. C., Meyers, D. A., Isaacs, W. B. and Xu, J. (2003) Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer. Prostate, 56, 37-44. (Pubitemid 36613154)
4. Wilbert, D. M., Griffin, J. E. and Wilson, J. D. (1983) Characterization of the cytosol androgen receptor of the human prostate. J. Clin. Endocrinol. Metab., 56, 113-120. (Pubitemid 13212316)
5. Makridakis, N. M., Ross, R. K., Pike, M. C., Crocitto, L. E., Kolonel, L. N., Pearce, C. L., Henderson, B. E. and Reichardt, J. K. (1999) Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African- American and Hispanic men in Los Angeles, USA. Lancet, 354, 975-978. (Pubitemid 29438402)
6. Makridakis, N., Ross, R. K., Pike, M. C. et al. (1997) A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res., 57, 1020-1022. (Pubitemid 27138592)
7. Davis, D. L. and Russell, D. W. (1993) Unusual length polymorphism in human steroid 5 alpha-reductase type 2 gene (SRD5A2). Hum. Mol. Genet., 2, 820. (Pubitemid 23197537)
8. Ross, R. K., Coetzee, G. A., Reichardt, J., Skinner, E. and Henderson, B. E. (1995) Does the racial-ethnic variation in prostate cancer risk have a hormonal basis? Cancer, 75, 1778-1782.
9. Kantoff, P. W., Febbo, P. G., Giovannucci, E., Krithivas, K., Dahl, D. M., Chang, G., Hennekens, C. H., Brown, M. and Stampfer, M. J. (1997) A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol. Biomarkers Prev., 6, 189-192. (Pubitemid 27118466)
10. Woolf, B. (1955) On estimating the relation between blood group and disease. Ann. Hum. Genet., 19, 251-253.
11. Lau, J., Ioannidis, J. P. and Schmid, C. H. (1997) Quantitative synthesis in systematic reviews. Ann. Intern. Med., 127, 820-826. (Pubitemid 27465551)
12. Petitti, D. B. (1994) Meta-analysis, Decision Analysis, and Costeffectiveness Analysis. Oxford University Press, New York, NY, USA.
13. Egger, M., Davey Smith, G., Schneider, M. and Minder, C. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-634. (Pubitemid 27387172)
14. Lindstrom, S., Wiklund, F., Adami, H. O., Balter, K. A., Adolfsson, J. and Gronberg, H. (2006) Germ-line genetic variation in the key androgenregulating genes androgen receptor, cytochrome P450, and steroid-5-alphareductase type 2 is important for prostate cancer development. Cancer Res., 66, 11077-11083. (Pubitemid 44877009)
15. Lindstrom, S., Zheng, S. L., Wiklund, F. et al. (2006) Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate, 66, 1729-1743. (Pubitemid 44893899)
16. Febbo, P. G., Kantoff, P. W., Platz, E. A., Casey, D., Batter, S., Giovannucci, E., Hennekens, C. H. and Stampfer, M. J. (1999) The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. Cancer Res., 59, 5878-5881. (Pubitemid 30004943)
17. Nam, R. K., Toi, A., Vesprini, D. et al. (2001) V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology, 57, 199-204. (Pubitemid 32065856)
18. Nam, R. K., Zhang, W. W., Trachtenberg, J. et al. (2003) Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 12, 1429-1437. (Pubitemid 38031745)
19. Lamharzi, N., Johnson, M. M., Goodman, G., Etzioni, R., Weiss, N. S., Dightman, D. A., Barnett, M., DiTommaso, D. and Chen, C. (2003) Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer. Int. J. Cancer, 105, 480-483. (Pubitemid 36578550)
20. Scariano, J. K., Treat, E., Alba, F., Nelson, H., Ness, S. A. and Smith, A. Y. (2008) The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer. Prostate, 68, 1798-1805.
21. Neslund-Dudas, C., Bock, C. H., Monaghan, K., Nock, N. L., Yang, J. J., Rundle, A., Tang, D. and Rybicki, B. A. (2007) SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate, 67, 1654-1663. (Pubitemid 350036951)
22. Onen, I. H., Ekmekci, A., Eroglu, M., Polat, F. and Biri, H. (2007) The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol., 26, 100-107. (Pubitemid 46363875)
23. Berndt, S. I., Chatterjee, N., Huang, W. Y., Chanock, S. J., Welch, R., Crawford, E. D. and Hayes, R. B. (2007) Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 16, 165-168. (Pubitemid 46174281)
24. Hayes, V. M., Severi, G., Padilla, E. J. et al. (2007) 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int. J. Cancer, 120, 776-780. (Pubitemid 46175396)
25. Sobti, R. C., Onsory, K., Al-Badran, A. I., Kaur, P., Watanabe, M., Krishan, A. and Mohan, H. (2006) CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol., 25, 287-294. (Pubitemid 43830442)
26. Salam, M. T., Ursin, G., Skinner, E. C., Dessissa, T. and Reichardt, J. K. (2005) Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol. Oncol., 23, 246-253. (Pubitemid 40961936)
27. Li, Z., Habuchi, T., Mitsumori, K., Kamoto, T., Kinoshitu, H., Segawa, T., Ogawa, O. and Kato, T. (2003) Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J. Urol., 169, 2378-2381. (Pubitemid 36576804)
28. Soderstrom, T., Wadelius, M., Andersson, S. O., Johansson, J. E., Johansson, S., Granath, F. and Rane, A. (2002) 5alpha-Reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics, 12, 307-312. (Pubitemid 34620658)
29. Latil, A. G., Azzouzi, R., Cancel, G. S., Guillaume, E. C., Cochan- Priollet, B., Berthon, P. L. and Cussenot, O. (2001) Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer, 92, 1130-1137. (Pubitemid 32861661)
30. Yamada, Y., Watanabe, M., Murata, M. et al. (2001) Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int. J. Cancer, 92, 683-686. (Pubitemid 32385710)
31. Lunn, R. M., Bell, D. A., Mohler, J. L. and Taylor, J. A. (1999) Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis, 20, 1727-1731. (Pubitemid 29410551)
32. Pearce, C. L., Makridakis, N. M., Ross, R. K., Pike, M. C., Kolonel, L. N., Henderson, B. E. and Reichardt, J. K. (2002) Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidemiol. Biomarkers Prev., 11, 417-418. (Pubitemid 34408223)
33. Hsing, A. W., Chen, C., Chokkalingam, A. P. et al. (2001) Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev., 10, 1077-1082. (Pubitemid 32959155)
34. Margiotti, K., Sangiuolo, F., De Luca, A. et al. (2000) Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients. Dis. Markers, 16, 147-150. (Pubitemid 32591572)
35. Forrest, M. S., Edwards, S. M., Houlston, R. et al. (2005) Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis., 8, 95-102.
36. Rajender, S., Vijayalakshmi, K., Pooja, S., Madhavi, S., Paul, S. F., Vettriselvi, V., Shroff, S., Singh, L. and Thangaraj, K. (2009) Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men. J. Androl., 30, 703-710.
37. Sarma, A. V., Dunn, R. L., Lange, L. A., Ray, A., Wang, Y., Lange, E. M. and Cooney, K. A. (2008) Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate, 68, 296-305. (Pubitemid 351273059)
38. Torkko, K. C., van Bokhoven, A., Mai, P. et al. (2008) VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non- Hispanic White and Hispanic White men. Clin. Cancer Res., 14, 3223-3229.
39. Cunningham, J. M., Hebbring, S. J., McDonnell, S. K. et al. (2007) Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol. Biomarkers Prev., 16, 969-978. (Pubitemid 46910099)
40. Pearce, C. L., Van Den Berg, D. J., Makridakis, N., Reichardt, J. K., Ross, R. K., Pike, M. C., Kolonel, L. N. and Henderson, B. E. (2008) No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. Hum. Mol. Genet., 17, 2456-2461.
41. Mononen, N., Ikonen, T., Syrjakoski, K., Matikainen, M., Schleutker, J., Tammela, T. L., Koivisto, P. A. and Kallioniemi, O. P. (2001) A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br. J. Cancer, 84, 1344-1347. (Pubitemid 32522102)
42. Giwercman, Y. L., Abrahamsson, P. A., Giwercman, A., Gadaleanu, V. and Ahlgren, G. (2005) The 5alpha-reductase type II A49T and V89L highactivity allelic variants are more common in men with prostate cancer compared with the general population. Eur. Urol., 48, 679-685. (Pubitemid 41278596)
43. Sobti, R. C., Gupta, L., Singh, S. K., Seth, A., Kaur, P. and Thakur, H. (2008) Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population. Cancer Genet. Cytogenet., 185, 78-85.
44. Gleason, D. F. and Mellinger, G. T. (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol., 111, 58-64.
45. Swanson, J. (2003) Problems in staging prostate cancer. J. Insur. Med., 35, 201-204.
46. Ntais, C., Polycarpou, A. and Ioannidis, J. P. (2003) SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev., 12, 618-624. (Pubitemid 36899841)
47. Li, J., Coates, R. J., Gwinn, M. and Khoury, M. J. (2010) Steroid 5- {alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review. Am. J. Epidemiol., 171, 1-13.
48. Cussenot, O., Azzouzi, A. R., Nicolaiew, N., Mangin, P., Cormier, L., Fournier, G., Valeri, A. and Cancel-Tassin, G. (2007) Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur. Urol., 52, 1082-1087.
49. Wang, C., Tao, W., Chen, Q., Hu, H., Wen, X. Y. and Han, R. (2010) SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis. Prostate, 70, 170-178.
50. Herman, C. M., Kattan, M. W., Ohori, M., Scardino, P. T. and Wheeler, T. M. (2001) Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am. J. Surg. Pathol., 25, 657-660. (Pubitemid 32423365)
51. Epstein, J. I., Partin, A. W., Sauvageot, J. and Walsh, P. C. (1996) Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am. J. Surg. Pathol., 20, 286-292. (Pubitemid 26071509)
52. Ohori, M., Wheeler, T. M. and Scardino, P. T. (1994) The New American Joint Committee on cancer and International Union against cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer, 74, 104-114. (Pubitemid 24187618)
53. Schroder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K. and Pavone-Macaluso, M. (1992) The TNM classification of prostate cancer. Prostate Suppl., 4, 129-138.
54. May, F., Hartung, R. and Breul, J. (2001) The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy. BJU Int, 88, 702-707.
55. Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G. and Balk, S. P. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res., 66, 2815-2825.
56. Tindall, D. J. and Rittmaster, R. S. (2008) The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J. Urol., 179, 1235-1242.
57. Heinlein, C. A. and Chang, C. (2004) Androgen receptor in prostate cancer. Endocr. Rev., 25, 276-308. (Pubitemid 38501396)
58. Thomas, L. N., Douglas, R. C., Lazier, C. B., Gupta, R., Norman, R. W., Murphy, P. R., Rittmaster, R. S. and Too, C. K. (2008) Levels of 5alphareductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J. Urol., 179, 147-151. (Pubitemid 350216746)
59. Montgomery, B. (2007) Prostate cancer. Aust. Fam. Physician, 36, 888.